Storm Therapeutics

Storm Therapeutics, is a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, opening up novel therapeutic targets in cancer treatment. Storm Therapeutics is based in Cambridge, UK.

http://www.stormtherapeutics.com

Team Member
more about
Hakan Goker
Latest News Entry
2017/11/06
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research

STORM Therapeutics, the drug discovery company focused on the
discovery of small molecule therapies modulating RNA epigenetics, today announced the
appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution
of its management and advisory networks as it fulfils its ambition to become the leading therapeutics
company in RNA epigenetic modulation.

2017/10/26
Taking RNA epigenetics by Storm

Storm is tapping the nascent field of RNA epigenetics for cancer

2017/07/27
Storm Therapeutics expands collaboration with Evotec on Storm's RNA Epigenetics Platform

STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery

2017/02/24
Storm Therapeutics appoints CEO and Chairman

CAMBRIDGE, UK (24 FEB 2017) - Storm Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.

2016/06/28
Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics

Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics
28 June 2016
Cambridge, UK - Storm Therapeutics, a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, has secured £12 million in series ‘A’ funding from Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments.
Storm Therapeutics is based upon the ground-breaking work of its founders, Professor Tony Kouzarides and Professor Eric Miska, in the field of RNA epigenetics.

all related news
all portfolio news